Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Studies from University of Notre Dame have provided new data on cancer vaccines
January 7th, 2009
According to a study from the United States, "The addition of adjuvants frequently enhances the efficacy of vaccine preparations. Interest in the use of vaccines as a means to treat cancer has led to the search for improved adjuvants." "Because cancer vaccines based on whole cell preparations might benefit from an adjuvant which enhances expression of antigens expressed during tumor cell growth, we evaluated the utility of an extracellular matrix material, porcine small intestinal submucosa (SIS), as a cancer vaccine adjuvant. After tumors were produced in Lobund-Wistar (LW) rats by subcutaneous administration of PAIII prostate adenocarcinoma cells, rats underwent...
Source: Vaccine Weekly (2009-01-07)
|
